tradingkey.logo

INmune Bio Reports Key Findings From Phase 2 MINDFuL Trial Of Xpro In Early Alzheimer’s Disease

ReutersJun 30, 2025 11:34 AM

- INmune Bio Inc INMB.O:

  • INMUNE BIO REPORTS KEY FINDINGS FROM PHASE 2 MINDFUL TRIAL OF XPRO™ IN EARLY ALZHEIMER’S DISEASE

  • INMUNE BIO INC - PHASE 2 MINDFUL TRIAL DID NOT MEET PRIMARY COGNITIVE ENDPOINT IN MITT POPULATION

  • INMUNE BIO INC - XPRO TREATMENT WELL-TOLERATED AND SAFE IN HIGH RISK APOE4+/+ PATIENTS

  • INMUNE BIO INC - TO SCHEDULE END-OF-PHASE 2 MEETING WITH FDA IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI